Varicella-zoster virus encephalitis with evolution to possible autoimmune encephalitis: a case report
Abstract
Case Presentation: A 75-year-old patient with dialysis-dependent chronic kidney disease due to probable Alport syndrome was admitted because of progressive mental confusion for one month, associated with incomplete right third cranial nerve palsy. On admission, lumbar puncture revealed pleocytosis (55 leukocytes/mm³, 93% lymphocytes), elevated protein levels (57 mg/dL), and a molecular panel for infectious encephalitis positive for Varicella-zoster virus (VZV). Intravenous acyclovir therapy was therefore initiated for 14 days. At the end of treatment, a repeat lumbar puncture demonstrated persistent pleocytosis and hyperproteinorrachia, with no clinical improvement. Consequently, antiviral therapy was extended to 28 days. However, despite normalization of cerebrospinal fluid findings, the patient exhibited marked worsening of cognitive and behavioral status, developing seizures and a new epileptiform focus on electroencephalogram. High-dose methylprednisolone pulse therapy was administered for five days, considering the possibility of autoimmune encephalitis secondary to the viral insult, but unfortunately no significant clinical response was observed. Discussion: Viral encephalitis is a relevant cause of central nervous system inflammation, with herpesviruses accounting for a substantial proportion of cases. Among them, Varicella-zoster virus is a recognized cause of encephalitis and may induce neurological damage through direct viral replication or immune-mediated mechanisms. In recent years, secondary autoimmune encephalitis following viral encephalitis has been increasingly recognized. This phenomenon was initially described more frequently after infection with Herpes simplex virus type 1, but growing evidence indicates that VZV infection may also trigger autoimmune responses in the central nervous system. The proposed pathophysiological mechanism involves neuronal injury caused by the initial viral infection, leading to the release of neuronal antigens and activation of an intrathecal immune response. This process may result in the production of autoantibodies directed against neuronal or glial structures, including antibodies against the N-methyl-D-aspartate receptor (anti-NMDAR) and glial fibrillary acidic protein (GFAP). Detection of these antibodies represents an important diagnostic marker for autoimmune encephalitis, although such tests are not widely available in the public healthcare system. Final Comments: In the present case, the persistence of cerebrospinal fluid pleocytosis associated with lack of clinical improvement after appropriate antiviral therapy raised suspicion of a secondary immune-mediated inflammatory process. The patient developed persistent neurological dysfunction and ongoing inflammatory cerebrospinal fluid abnormalities despite adequate antiviral treatment. This case highlights the diagnostic challenges in resource-limited settings and underscores the importance of recognizing autoimmune encephalitis as a potential complication following viral encephalitis.